The Production of Therapeutic Proteins in Plants: Apo AI and Insulin

More documents

Recommendations

Info

Biosimilar Insulin (SBS-1000)• Very well characterized biologic with establishedmonograph assays and reference standards• FTO – very little restricting intellectual property• Unmet need – increasing incidence of diabetesworld wide with limited supply• Reduced manufacturing costs – allows accessibilityfor poorer countries
Economics of Plant-Produced InsulinSafflowerEnabling technology to meetinsulin demand1.2 %~1.0insulin expression oftotal seed proteinacre produces 1 kg of insulinFloretSeed15,000acres to supply 2012projected insulin demandworld-wide$80Mest. capital cost for 1,000 kgof plant-produced insulin70%Capital costreductioncompared tofermentation
Page 1 and 2: The Production of Therapeutic Prote
Page 3 and 4: SemBioSys OverviewLocation: Calgary
Page 5 and 6: SemBioSys’ TechnologyProof-of-Con
Page 7 and 8: Field Grown GMO SafflowerPlanting s
Page 9 and 10: Purification of OilbodiesThe Proces
Page 11 and 12: Plant Impurity AssaysPhytate (IP 6
Page 13 and 14: Product Impurity Assays - Fusion Pa
Page 15 and 16: Viral Load/Viral ClearanceRegulator
Page 17: InsulinPositioned to Meet the Growi
Page 21 and 22: Insulin - Equivalence DataV8 Protea
Page 23 and 24: Insulin - Equivalence DataIGF-1 Rec
Page 25 and 26: Insulin Characterization: Clinical
Page 27 and 28: Apo AI Milano (SBS-2000)• FTO - S
Page 29 and 30: Functional Characterization of Puri
Page 31 and 32: Cholesterol Mobilization in vivoSBS
Page 33: Non-Pharma ProductsProducts and Com

The Production of Therapeutic Proteins in Plants: Apo AI and Insulin

Create successful ePaper yourself

Delete template?

Save as template?